INTENSITY THERAPEUTICS INC Stock Price, News & Analysis

Intensity Therapeutics (Nasdaq: INTS) was granted a 180-calendar-day extension by Nasdaq to regain compliance with the exchange's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).

The initial 180-day period expired on December 3, 2025; the new compliance deadline is June 1, 2026. To regain compliance the company must maintain a closing bid of at least $1.00 per share for ten consecutive business days on or before June 1, 2026. The notification does not affect listing or trading, and shares will continue to trade on the Nasdaq Capital Market under the symbol INTS. The company said it will monitor the closing bid and take actions as needed to cure the deficiency before the end of the extension period.

Intensity Therapeutics (Nasdaq: INTS) announced two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX, taking place December 9–12, 2025.

Presentation 1: "Accelerating an Anthracycline-Free Future" — poster #801 (PS4-10-15) presented by Lewis Bender on Dec 11, 2025 at 5:00 PM CT. Presentation 2: INVINCIBLE-4-SAKK 66/22 Phase II early observations on intratumoral INT230-6 — poster #1589 (PS5-01-04) presented by Andreas Müller on Dec 12, 2025 at 12:00 PM CT.

Both presentations describe clinical and early clinical observations for INT230-6 and potential anthracycline‑sparing combinations in breast cancer therapy.

Intensity Therapeutics (Nasdaq: INTS) reported Q3 2025 results and a corporate update on Nov 6, 2025. Key points: the company had $7.1 million cash as of Sept 30, 2025 and raised an additional $6.1 million in Q4 2025, extending cash runway to the end of Q1 2027.

Clinical: a peer‑reviewed IT‑01 manuscript reported a 75% disease control rate (48/64) and median overall survival of 11.9 months; a metastatic sarcoma subset mOS was 21.3 months. An exploratory >40% total tumor burden dosing subgroup showed mOS 18.7 vs 3.1 months (HR 0.17; P<0.0001). No dose‑limiting toxicities reported.

Program updates: INVINCIBLE‑4 dosing will be amended and enrollment expected to restart in Q1 2026; INVINCIBLE‑3 remains paused after 21 patients due to funding.

Intensity Therapeutics (Nasdaq: INTS) announced a registered direct offering of 5,000,000 shares of common stock at $0.80 per share for gross proceeds of approximately $4.0 million. The offering is expected to close on or about November 3, 2025, subject to customary closing conditions.

The company expects to use net proceeds to advance clinical trials, for working capital and general corporate purposes, and expects the cash runway to extend until the end of Q1 2027. A.G.P./Alliance Global Partners is acting as sole placement agent. The offering is being made under an effective Form S-3 registration statement declared effective July 11, 2024.

Intensity Therapeutics (Nasdaq: INTS) announced publication in eBioMedicine of phase 1/2 results for intratumoral INT230-6 in metastatic or refractory solid tumors (Online First Oct 29, 2025).

Key outcomes: disease control rate 75% (48/64), overall median survival 11.9 months, sarcoma subset mOS 21.3 months. In an exploratory analysis treating >40% total tumor burden, mOS was 18.7 months vs 3.1 months when <40% treated (HR 0.17; P<0.0001). Approximately 20% of >40% patients showed uninjected tumor shrinkage (abscopal effects). Safety: no dose‑limiting toxicities, grade 3 events in 10.9%, no grade 4/5 treatment‑related AEs. Pharmacokinetics: >95% of active agents remained in injected tumors. The company will host an author webinar on Oct 31, 2025 at 9:00 AM ET.

Intensity Therapeutics (NASDAQ:INTS) has reported an update on its INVINCIBLE-4 trial for triple-negative breast cancer treatment. The company achieved a significant milestone with a pathological complete response (pCR) in the first evaluated patient from Cohort A, where patients receive two doses of INT230-6 before standard immunochemotherapy.

While safety in Cohort A has been generally favorable and patients show significant tumor necrosis, the trial has temporarily paused new enrollment due to localized skin irritation in some patients. The company plans to evaluate the data and implement necessary modifications to the INT230-6 dosing regimen before resuming enrollment. The pause was a company decision, not a regulatory directive.

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotech company specializing in intratumoral cancer therapies, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.

CEO Lewis H. Bender will engage in a fireside chat with Dr. Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright. The discussion will be available on-demand for registered conference attendees starting September 5, 2025, at 7:00 AM ET.

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotech company, has successfully regained compliance with Nasdaq's minimum Stockholders' Equity Requirement. The company confirmed having at least $2.5 million in stockholders' equity as of June 30, 2025, following successful fundraising efforts through July 2025.

Intensity, which focuses on developing novel intratumoral cancer therapies using its proprietary non-covalent conjugation technology, received confirmation from Nasdaq's Listing Qualifications Staff on August 8, 2025. CEO Lewis H. Bender stated that the company now projects having sufficient cash to fund operations into the second half of 2026.

Intensity Therapeutics (NASDAQ:INTS) reported Q2 2025 financial results and provided updates on its clinical trials. The company successfully raised over $11.3 million since Q2 2025, extending its cash runway into H2 2026. The INVINCIBLE-4 Study, testing INT230-6 in triple-negative breast cancer, showed promising early results with high tumor necrosis achieved in 8 days.

The company's Phase 3 INVINCIBLE-3 Study for soft tissue sarcoma has temporarily paused new enrollments due to previous funding constraints, though existing patients continue treatment. Q2 financial results showed reduced losses, with net loss decreasing to $2.5 million from $5.0 million year-over-year. R&D expenses decreased to $1.5 million from $3.6 million, while G&A expenses reduced to $1.2 million from $1.5 million.